A Phase 3 interventional study of PP3M 175 mg eq. and PP3M 263 mg eq. in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 53 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-05-11.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 16th largest by enrollment, is one of 5 that started in 2012, is one of 41 in phase 3, and was the 71st registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 509 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 25th largest by enrollment of the 176 interventional ones that give a count, is one of 7 that started in 2012, is one of 74 in phase 3, and was the 157th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
This is a randomized (the study drug is assigned by chance), double blind (neither physician nor patient knows the treatment that the patient receives), parallel group (each group of patients will be treated at the same time), placebo-controlled (an inactive substance is compared with a drug to test whether the drug has a real effect in a clinical trial) multicenter study. The study consists of 4 phases: a Screening Phase (up to 3 weeks); a 17-week flexible dose open-label Transition Phase (open-label phase means that all people know the identity of the intervention); a 12-week fixed dose open-label Maintenance Phase; and a randomized, double-blind, fixed dose, placebo-controlled relapse prevention phase (referred to as the Double-blind Phase). Patients who meet specific stabilization criteria will enter the Double-blind Phase at Week 29. Patients will be randomly assigned, in a 1:1 ratio, to receive either a fixed dose of PP3M or placebo. The Double-blind Phase will be of variable duration; patients will remain in the study until they experience a relapse event or meet discontinuation criteria.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PP3M 175 mg eq. · Drug: PP3M 263 mg eq. · Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq.
Drug: Placebo (20% Intralipid emulsion)
Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Time to Relapse During the Double-Blind Phase
Time to relapse defined as the time between participant randomization into the double blind Phase and the first documentation of a relapse event. Median time to relapse was estimated by the Kaplan-Meier method.
Time frame: Approximately Week 60
Change in Positive and Negative Syndrome Scale (PANSS) (Total Score) From Baseline to Endpoint in the Double-Blind Phase
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items). Each item is rated 1 (absent) to 7 (extreme). The total score ranging from 30 to 210. Higher scores indicate more severe neuropsychiatric symptoms of schizophrenia.
Time frame: Baseline (Day 1 prior to randomization) and Endpoint (Approximately Week 60)
Change in Clinical Global Impression Severity (CGI-S) Scale From Baseline to Endpoint in the Double-Blind Phase
The CGI-S rating scale is used to rate the severity of a participant's overall clinical condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe).
Time frame: Baseline (Day 1 prior to randomization) and Endpoint (Approximately Week 60)
Change in Personal and Social Performance (PSP) Scale From Baseline to Endpoint in the Double-Blind Phase
The PSP scale measures personal and social functioning in the domains of: a) Socially useful activities, b) Personal and social relationships, c) Self-care, and d) Disturbing and aggressive behavior. The results of the assessment were converted to a numerical score which ranges from 1 to 100. A score lying between 71 and 100 indicates a mild degree of dysfunction; scores between 31 and 70 indicate varying degrees of difficulty, and a participant with a score of \<=30 had functioning so poor that he or she required intensive supervision.
Time frame: Baseline (Day 1 prior to randomization) and Endpoint (Approximately Week 60)
| Milestone | Open-Label Transition Phase: Paliperidone Palmitate 1-Month | Open-Label Maintenance Phase: Paliperidone Palmitate 3-Month | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|---|---|
| Started | 506 | 0 | 0 | 0 |
| Completed | 379 | 0 | 0 | 0 |
| Not completed | 127 | 0 | 0 | 0 |
| Withdrew: Adverse event | 16 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 19 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 19 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 51 | 0 | 0 | 0 |
| Withdrew: Failed maintenance phase criteria | 8 | 0 | 0 | 0 |
| Withdrew: Other | 9 | 0 | 0 | 0 |
| Milestone | Open-Label Transition Phase: Paliperidone Palmitate 1-Month | Open-Label Maintenance Phase: Paliperidone Palmitate 3-Month | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|---|---|
| Started | 0 | 379 | 0 | 0 |
| Completed | 0 | 305 | 0 | 0 |
| Not completed | 0 | 74 | 0 | 0 |
| Withdrew: Adverse event | 0 | 10 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 9 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 5 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 12 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 15 | 0 | 0 |
| Withdrew: Failed randomization criteria | 0 | 13 | 0 | 0 |
| Withdrew: Other | 0 | 10 | 0 | 0 |
| Milestone | Open-Label Transition Phase: Paliperidone Palmitate 1-Month | Open-Label Maintenance Phase: Paliperidone Palmitate 3-Month | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|---|---|
| Started | 0 | 0 | 145 | 160 |
| Completed | 0 | 0 | 122 | 148 |
| Not completed | 0 | 0 | 23 | 12 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 10 | 7 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 9 | 2 |
Time to relapse defined as the time between participant randomization into the double blind Phase and the first documentation of a relapse event. Median time to relapse was estimated by the Kaplan-Meier method.
| Days | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|
| Time to Relapse During the Double-Blind Phase | 395.0 (274.0 to NA) | NA (NA to NA) |
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items). Each item is rated 1 (absent) to 7 (extreme). The total score ranging from 30 to 210. Higher scores indicate more severe neuropsychiatric symptoms of schizophrenia.
| Units on a Scale | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|
| Baseline | 54.3 ± 9.20 | 54.8 ± 9.96 |
| Change at Endpoint (Approximately Week 60) | 6.7 ± 14.40 | -0.5 ± 8.36 |
The CGI-S rating scale is used to rate the severity of a participant's overall clinical condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe).
| Units on a Scale | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|
| Baseline | 2.8 ± 0.65 | 2.7 ± 0.68 |
| Change at Endpoint (Approximately Week 60) | 0.4 ± 0.87 | 0.1 ± 0.60 |
The PSP scale measures personal and social functioning in the domains of: a) Socially useful activities, b) Personal and social relationships, c) Self-care, and d) Disturbing and aggressive behavior. The results of the assessment were converted to a numerical score which ranges from 1 to 100. A score lying between 71 and 100 indicates a mild degree of dysfunction; scores between 31 and 70 indicate varying degrees of difficulty, and a participant with a score of \<=30 had functioning so poor that he or she required intensive supervision.
| Units on a Scale | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|
| Baseline | 68.5 ± 8.93 | 68.9 ± 9.34 |
| Change at Endpoint (Approximately Week 60) | -4.2 ± 9.70 | -0.5 ± 6.63 |
Collected over Up to Week 92. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label Phase: PP1M + PP3M | — | 33/506 (6.5%) | 317/506 (62.6%) |
| Double-Blind Phase: Placebo | — | 15/145 (10.3%) | 77/145 (53.1%) |
| Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) | — | 4/160 (2.5%) | 98/160 (61.3%) |
| Event | Open-Label Phase: PP1M + PP3M | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 12/506 | 11/145 | 1/160 |
| Psychotic DisorderPsychiatric disorders | 9/506 | 0/145 | 0/160 |
| Suicide AttemptPsychiatric disorders | 0/506 | 0/145 | 2/160 |
| CellulitisInfections and infestations | 0/506 | 1/145 | 0/160 |
| Transaminases IncreasedInvestigations | 0/506 | 1/145 | 0/160 |
| AnxietyPsychiatric disorders | 1/506 | 1/145 | 0/160 |
| Suicidal IdeationPsychiatric disorders | 2/506 | 1/145 | 0/160 |
| Schizophrenia, Paranoid TypePsychiatric disorders | 1/506 | 0/145 | 1/160 |
| Hallucination, AuditoryPsychiatric disorders | 2/506 | 0/145 | 0/160 |
| Gastritis ErosiveGastrointestinal disorders | 1/506 | 0/145 | 0/160 |
| Event | Open-Label Phase: PP1M + PP3M | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) |
|---|---|---|---|
| InsomniaPsychiatric disorders | 50/506 | 17/145 | 11/160 |
| AnxietyPsychiatric disorders | 43/506 | 15/145 | 13/160 |
| Weight IncreasedInvestigations | 51/506 | 5/145 | 14/160 |
| HeadacheNervous system disorders | 33/506 | 6/145 | 14/160 |
| Injection Site PainGeneral disorders | 44/506 | 0/145 | 2/160 |
| Weight DecreasedInvestigations | 8/506 | 11/145 | 2/160 |
| NasopharyngitisInfections and infestations | 14/506 | 2/145 | 9/160 |
| SchizophreniaPsychiatric disorders | 4/506 | 8/145 | 1/160 |
| AkathisiaNervous system disorders | 17/506 | 1/145 | 7/160 |
| Upper Respiratory Tract InfectionInfections and infestations | 9/506 | 3/145 | 6/160 |
| Age, Continuous(years) | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) | Total |
|---|---|---|---|
| Mean | 38.5 ± 11.16 | 37.1 ± 10.87 | 37.8 ± 11.01 |
| Sex: Female, Male(Participants) | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) | Total |
|---|---|---|---|
| Female | 35 | 42 | 77 |
| Male | 110 | 118 | 228 |
| Region of Enrollment(participants) | Double-Blind Phase: Placebo | Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M) | Total |
|---|---|---|---|
| Colombia | 12 | 13 | 25 |
| Malaysia | 11 | 12 | 23 |
| Mexico | 10 | 8 | 18 |
| Romania | 14 | 13 | 27 |
| South Korea | 4 | 2 | 6 |
| Turkey | 5 | 6 | 11 |
| Ukraine | 63 | 74 | 137 |
| United States | 26 | 32 | 58 |
The record gives a start of May 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Research & Development, LLC →